ProCE Banner Activity

Integrating New Agents and Advances Into Current Prostate Cancer Treatment

Clinical Thought
In this commentary, 3 prostate cancer experts discuss recent advances in treating patients with prostate cancer, including use of GnRH antagonists and androgen receptor inhibitors and the management of patients with comorbidities.

Released: November 02, 2021

Expiration: November 01, 2022

Share

Faculty

Daniel W. Lin

Daniel W. Lin, MD

Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Alicia K. Morgans

Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

David F. Penson

David F. Penson, MD, MPH

Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Bayer Healthcare Pharma

Myovant Sciences Ltd

Pfizer, Inc.

Faculty Disclosure

Primary Author

Daniel W. Lin, MD

Professor and Chief of Urologic Oncology
Department of Urology
University of Washington
Seattle, Washington

Daniel W. Lin, MD, has disclosed that he has received funds for research support from Decipher, Genomic Health, MagForce USA, and MDxHealth; consulting fees from Astellas, Clovis Oncology, and Janssen; and other financial or material support from AstraZeneca.

Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, MPH, has disclosed that she has received funds for research support from Bayer, Dendreon, Myovant, Sanofi, and Seattle Genetics and consulting fees from AAA, AstraZeneca, Astellas, Bayer, Blue Earth, Clovis, Dendreon, Exelixis, Janssen, Myovant, Myriad, Novartis, Pfizer, Sanofi, and Seattle Genetics.

David F. Penson, MD, MPH

Professor and Chair
Department of Urology
Vanderbilt University School of Medicine
Nashville, Tennessee

David F. Penson, MD, MPH, has no relevant conflict of interest to report.